Role of GLP1a drugs after TAVI: insights from the MOTIVE registry
GLP-1 receptor agonists (GLP-1a) are a novel class of cardiometabolic drugs that have been shown to reduce the risk of major adverse cardiovascular events (MACE) and cardiovascular mortality in patients with type 2 diabetes, overweight, or obesity. Improved outcomes have also been reported in patients undergoing...